Looking At The Narrative For CME Group (CME) As Analyst Views Shift

Simply Wall St

Thu, February 12, 2026 at 5:11 PM GMT+9 5 min read

In this article:

CME

-1.40%

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.

CME Group’s fair value estimate has been nudged higher to roughly US$296.71 per share, with the discount rate trimmed to around 7.90% and revenue growth assumptions lifted to about 5.44%. This reflects a fresh round of recalibration from the analyst community. These tweaks sit against a backdrop where several bullish research shops have raised their price targets and one major bank has adjusted its view in both directions, highlighting both interest in the story and some ongoing debate around how optimistic to be on future revenues. Stay tuned as we walk through what these shifting targets mean for you and how you can keep on top of the evolving narrative around CME Group.

Stay updated as the Fair Value for CME Group shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on CME Group.

What Wall Street Has Been Saying

🐂 Bullish Takeaways

Several firms, including UBS, RBC Capital, JPMorgan, TD Cowen, Morgan Stanley and Barclays, have recently raised their CME Group price targets by amounts ranging from US$4 to US$30, which signals a generally constructive tone on the shares.

TD Cowen has shifted to a more positive stance on CME Group, upgrading the stock to Buy in mid January and later lifting its price target by US$23. This points to increased confidence in the company’s execution and growth opportunities.

Across the recent research, analysts are effectively rewarding CME Group for perceived solid execution, cost discipline, transparency with investors and the potential for continued growth momentum in its business mix.

Even where reports stay neutral on the rating, the series of higher targets from banks such as Morgan Stanley, Barclays and RBC Capital indicates that many on the Street see scope for further value in CME Group relative to their prior assumptions.

🐻 Bearish Takeaways

The research flow is not one sided. Morgan Stanley cut its target by US$1 in January before later lifting it again, which underlines that some analysts remain cautious on how much upside is already reflected in CME Group’s share price.

Across the more restrained commentary, key reservations tend to cluster around valuation, the risk that recent optimism is already priced in and typical near term uncertainties that could affect how quickly CME Group delivers on the growth that bullish analysts are modeling.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!

Story Continues  

NasdaqGS:CME 1-Year Stock Price Chart

What’s in the News

FanDuel and CME Group launched the FanDuel Predicts app in Alabama, Alaska, South Carolina, North Dakota and South Dakota. This begins a phased rollout that is planned to reach all 50 states and offer event contracts on financial benchmarks, commodities, cryptocurrencies, economic indicators and sports where allowed.

The FanDuel Predicts platform uses full Know Your Customer checks and lets users buy or sell event contracts priced between US$0.01 and US$0.99 by choosing Yes or No outcomes. It includes built in consumer protection tools such as deposit limits, alerts, self exclusion and access to Kindbridge Behavior Health services.

CME Group introduced Spot Quoted XRP and SOL futures, expanding beyond its existing Spot Quoted Bitcoin and Ether futures. It is also extending this format across four major U.S. equity indices, giving traders futures exposure quoted in spot market terms with longer dated expiries.

The U.S. Securities and Exchange Commission approved registration of CME Securities Clearing Inc., a new securities clearing house that CME Group plans to launch in the second quarter of 2026 to support upcoming clearing mandates for U.S. Treasury and repo transactions.

How This Changes the Fair Value For CME Group

Fair Value: Revised slightly higher from about US$290.40 to roughly US$296.71 per share, which points to a modest uplift in the modeled price target you might use as a reference point.

Discount Rate: Trimmed from about 8.12% to around 7.90%, a shift that typically supports a higher present value for the cash flows that are being modeled.

Revenue Growth: Raised from roughly 4.61% to about 5.44%, so the latest assumptions reflect a somewhat stronger top line trajectory built into the forecasts.

Net Profit Margin: Adjusted down from about 54.65% to roughly 52.85%, indicating that the updated work incorporates a more conservative view on how much profit CME Group may retain from each dollar of revenue.

Future P/E: Marginally reduced from about 33.17x to roughly 32.94x, meaning the model is now applying a slightly lower valuation multiple to those forward earnings estimates.

🔔 Never Miss an Update: Follow The Narrative

Narratives on Simply Wall St let you connect a company’s story with its numbers by linking your view on the business to forecasts for revenue, earnings and margins, and then to a fair value estimate. Hosted on the Community page and used by millions of investors, Narratives are easy to follow and update automatically when fresh news, earnings or valuation work comes in. This allows you to compare Fair Value to Price and decide if it might be time to buy, hold or sell.

If CME Group is on your radar, it is worth seeing how the current Narrative ties the story to the latest fair value work.

How global demand for risk management, retail trading growth and EMEA/APAC expansion feed into volume, revenue and earnings assumptions.

What analysts are building in for future revenue of US$7.3b, earnings of US$4.3b, profit margins and a future P/E of 30.0x.

Which risks, from DeFi competition to periods of low volatility or regulatory change, could challenge the CME Group outlook.

Head over to the Simply Wall St Community and follow the CME Group Narrative at this link so you can keep track of how new data, forecasts and valuation views evolve over time. Curious how numbers become stories that shape markets? Explore Community Narratives

_ This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._

Companies discussed in this article include CME.

Have feedback on this article? Concerned about the content? Get in touch with us directly._ Alternatively, email editorial-team@simplywallst.com_

Terms and Privacy Policy

Privacy Dashboard

More Info